Adoptive transfer of Aspergillus-specific T cells as a novel anti-fungal therapy for hematopoietic stem cell transplant recipients: Progress and challenges

Critical Reviews in Oncology/Hematology

Volumn 98, Issue , 2016, Pages 62-72

  Papadopoulou, Anastasia ^a,b   Kaloyannidis, Panayotis ^c   Yannaki, Evangelia ^a,d   Cruz, Conrad Russell ^e  

^a G PAPANICOLAOU HOSPITAL   (Greece)

^b INFORMATION TECHNOLOGIES INSTITUTE   (Greece)

^c KING FAHAD SPECIALIST HOSPITAL   (Saudi Arabia)

^d UNIVERSITY OF WASHINGTON   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Aspergillus; Aspergillus specific T cells; Hematopoietic stem cell transplantation; Immunotherapy; Invasive aspergillosis; T cells

Indexed keywords

ANTIFUNGAL AGENT; FUNGUS ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ASPERGILLUS; BIOENGINEERING; CLINICAL PROTOCOL; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; INVASIVE ASPERGILLOSIS; NONHUMAN; REVIEW; T LYMPHOCYTE; TREATMENT RESPONSE; ASPERGILLOSIS; IMMUNOLOGY;

ADOPTIVE TRANSFER; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; T-LYMPHOCYTES;

EID: 84957427380     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.10.005     Document Type: Review

References (125)

1. Aliff T.B., Maslak P.G., Jurcic J.G., Heaney M.L., Cathcart K.N., Sepkowitz K.A., et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003, 97:1025-1032. 10.1002/cncr.11115.
2. Appay V., van Lier R.A.W., Sallusto F., Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008, 73:975-983. 10.1002/cyto.a.20643.
3. Armstrong-James D., Teo I.A., Shrivastava S., Petrou M.A., Taube D., Dorling A., et al. Exogenous interferon-gamma immunotherapy for invasive fungal infections in kidney transplant patients. Am. J. Transplant. 2010, 10:1796-1803. 10.1111/j.1600-6143.2010.03094.x.
4. Bacher P., Schink C., Teutschbein J., Kniemeyer O., Assenmacher M., Brakhage A.A., et al. Antigen-reactive T cell enrichment for direct, high-resolution analysis of the human naive and memory Th cell repertoire. J. Immunol. 2013, 190:3967-3976. 10.4049/jimmunol.1202221.
5. Bacher P., Kniemeyer O., Teutschbein J., Thön M., Vödisch M., Wartenberg D., et al. Identification of immunogenic antigens from Aspergillus fumigatus by direct multiparameter characterization of specific conventional and regulatory CD4+ T cells. J. Immunol. 2014, 193:3332-3343. 10.4049/jimmunol.1400776.
6. Baddley J.W., Andes D.R., Marr K.A., Kauffman C.A., Kontoyiannis D.P., Ito J.I., et al. Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med. Mycol. 2013, 51:128-135. 10.3109/13693786.2012.690108.
7. Balduzzi A., Lucchini G., Hirsch H.H., Basso S., Cioni M., Rovelli A., et al. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant. 2011, 46:987-992. 10.1038/bmt.2010.221.
8. Beck O., Topp M.S., Koehl U., Roilides E., Simitsopoulou M., Hanisch M., et al. Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood 2006, 107:2562-2569. 10.1182/blood-2005-04-1660.
9. Beck O., Koehl U., Tramsen L., Mousset S., Latgé J.P., Müller K., et al. Enumeration of functionally active anti-Aspergillus T-cells in human peripheral blood. J. Immunol. Methods 2008, 335:41-45. 10.1016/j.jim.2008.02.014.
10. Blyth E., Clancy L., Simms R., Ma C.K.K., Burgess J., Deo S., et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood 2013, 121:3745-3758. 10.1182/blood-2012-08-448977.
11. Bozza S., Gaziano R., Spreca A., Bacci A., Montagnoli C., di Francesco P., et al. Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus. J. Immunol. 2002, 168:1362-1371.
12. Bozza S., Gaziano R., Lipford G.B., Montagnoli C., Bacci A., Di Francesco P., et al. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect. 2002, 4:1281-1290.
13. Bozza S., Perruccio K., Montagnoli C., Gaziano R., Bellocchio S., Burchielli E., et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 2003, 102:3807-3814. 10.1182/blood-2003-03-0748.
14. Bozza S., Clavaud C., Giovannini G., Fontaine T., Beauvais A., Sarfati J., et al. Immune sensing of Aspergillus fumigatus proteins, glycolipids, and polysaccharides and the impact on Th immunity and vaccination. J. Immunol. 2009, 183:2407-2414. 10.4049/jimmunol.0900961.
15. Brakhage A.A., Bruns S., Thywissen A., Zipfel P.F., Behnsen J. Interaction of phagocytes with filamentous fungi. Curr. Opin. Microbiol. 2010, 13:409-415. 10.1016/j.mib.2010.04.009.
16. Bruns S., Kniemeyer O., Hasenberg M., Aimanianda V., Nietzsche S., Thywissen A., et al. Production of extracellular traps against Aspergillus fumigatus in vitro and in infected lung tissue is dependent on invading neutrophils and influenced by hydrophobin RodA. PLoS Pathog. 2010, 6:e1000873. 10.1371/journal.ppat.1000873.
17. Caira M., Girmenia C., Fadda R.M., Mitra M.E., Picardi M., Van Lint M.T., et al. Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk?. Eur. J. Haematol. 2008, 81:242-243. 10.1111/j.1600-0609.2008.01096.x.
18. Carvalho A., Cunha C., Bistoni F., Romani L. Immunotherapy of aspergillosis. Clin. Microbiol. Infect. 2012, 18:120-125. 10.1111/j.1469-0691.2011.03681.x.
19. Cenci E., Mencacci A., Fè d'Ostiani C., Del Sero G., Mosci P., Montagnoli C., et al. Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J. Infect. Dis. 1998, 178:1750-1760.
20. Cenci E., Mencacci A., Del Sero G., Bacci A., Montagnoli C., d'Ostiani C.F., et al. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J. Infect. Dis. 1999, 180:1957-1968. 10.1086/315142.
21. Cenci E., Mencacci A., Bacci A., Bistoni F., Kurup V.P., Romani L. T cell vaccination in mice with invasive pulmonary aspergillosis. J. Immunol. 2000, 165:381-388.
22. Chai L.Y.A., van de Veerdonk F., Marijnissen R.J., Cheng S.-C., Khoo A.L., Hectors M., et al. Anti-Aspergillus human host defence relies on type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity. Immunology 2010, 130:46-54. 10.1111/j.1365-2567.2009.03211.x.
23. Chamilos G., Ganguly D., Lande R., Gregorio J., Meller S., Goldman W.E., et al. Generation of IL-23 producing dendritic cells (DCs) by airborne fungi regulates fungal pathogenicity via the induction of T(H)-17 responses. PLoS One 2010, 5:e12955. 10.1371/journal.pone.0012955.
24. Chaudhary N., Staab J.F., Marr K.A. Healthy human T-Cell responses to Aspergillus fumigatus antigens. PLoS One 2010, 5:e9036. 10.1371/journal.pone.0009036.
25. Clemons K.V., Grunig G., Sobel R.A., Mirels L.F., Rennick D.M., Stevens D.A. Role of IL-10 in invasive aspergillosis: increased resistance of IL-10 gene knockout mice to lethal systemic aspergillosis. Clin. Exp. Immunol. 2000, 122:186-191.
26. Comoli P., Basso S., Zecca M., Pagliara D., Baldanti F., Bernardo M.E., et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am. J. Transplant. 2007, 7:1648-1655. 10.1111/j.1600-6143.2007.01823.x.
27. Cruz C.R., Hanley P.J., Liu H., Torrano V., Lin Y.-F., Arce J.A., et al. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy 2010, 12:743-749. 10.3109/14653241003709686.
28. Cruz C.R.Y., Lam S., Hanley P.J., Bear A.S., Langston C., Cohen A.J., Robust T., et al. cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy. Clin. Exp. Immunol. 2013, 174:89-96. 10.1111/cei.12156.
29. Cruz C.R.Y., Micklethwaite K.P., Savoldo B., Ramos C.A., Lam S., Ku S., et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013, 122:2965-2973. 10.1182/blood-2013-06-506741.
30. Dasbach E.J., Davies G.M., Teutsch S.M. Burden of aspergillosis-related hospitalizations in the United States. Clin. Infect. Dis. 2000, 31:1524-1528. 10.1086/317487.
31. Denning D.W., Hope W.W. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol. 2010, 18:195-204. 10.1016/j.tim.2010.02.004.
32. Denning D.W. Echinocandin antifungal drugs. Lancet 2003, 362:1142-1151. 10.1016/s0140-6736(03) 14472-8.
33. Dotti G., Gottschalk S., Savoldo B., Brenner M.K. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol. Rev. 2014, 257:107-126. 10.1111/imr.12131.
34. Doubrovina E., Oflaz-Sozmen B., Prockop S.E., Kernan N.A., Abramson S., Teruya-Feldstein J., et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012, 119:2644-2656. 10.1182/blood-2011-08-371971.
35. Dvorak C.C., Steinbach W.J., Brown J.M.Y., Agarwal R. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2005, 36:621-629. 10.1038/sj.bmt.1705113.
36. Einsele H., Roosnek E., Rufer N., Sinzger C., Riegler S., Löffler J., et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002, 99:3916-3922.
37. Feuchtinger T., Matthes-Martin S., Richard C., Lion T., Fuhrer M., Hamprecht K., et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br. J. Haematol. 2006, 134:64-76. 10.1111/j. 1365-2141.2006.06108. x.
38. Gattinoni L., Klebanoff C.A., Restifo N.P. Paths to stemness: building the ultimate antitumour T cell. Nat. Rev. Cancer 2012, 12:671-684. 10.1038/nrc3322.
39. Gaundar S.S., Clancy L., Blyth E., Meyer W., Gottlieb D.J. Robust polyfunctional T-helper 1 responses to multiple fungal antigens from a cell population generated using an environmental strain of Aspergillus fumigatus. Cytotherapy 2012, 14:1119-1130. 10.3109/14653249.2012.704013.
40. Gerdemann U., Katari U.L., Papadopoulou A., Keirnan J.M., Craddock J.A., Liu H., et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol. Ther. 2013, 21:2113-2121. 10.1038/mt.2013.151.
41. Ghannoum M.A., Rice L.B. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 1999, 12:501-517.
42. Grazziutti M., Przepiorka D., Rex J.H., Braunschweig I., Vadhan-Raj S., Savary C.A. Dendritic cell-mediated stimulation of the in vitro lymphocyte response to Aspergillus. Bone Marrow Transplant. 2001, 27:647-652. 10.1038/sj.bmt.1702832.
43. Gustafsson A., Levitsky V., Zou J.Z., Frisan T., Dalianis T., Ljungman P., et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000, 95:807-814.
44. Hackett P.B., Ekker S.C., Largaespada D.A., McIvor R.S. Sleeping beauty transposon-mediated gene therapy for prolonged expression. Adv. Genet. 2005, 54:189-232. 10.1016/S0065-2660(05).
45. Hamza N.S., Lisgaris M., Yadavalli G., Nadeau L., Fox R., Fu P., et al. Kinetics of myeloid and lymphocyte recovery and infectious complications after unrelated umbilical cord blood versus HLA-matched unrelated donor allogeneic transplantation in adults. Br. J. Haematol. 2004, 124:488-498.
46. Hasenberg M., Behnsen J., Krappmann S., Brakhage A., Gunzer M. Phagocyte responses towards Aspergillus fumigatus. Int J. Med. Microbiol. 2011, 301:436-444. 10.1016/j.ijmm.2011.04.012.
47. Haynes M.P., Chong P.L.-G., Buckley H.R., Pieringer R.A. Fluorescence studies on the molecular action of amphotericin B on susceptible and resistant fungal cells. Biochemistry 1996, 35:7983-7992. 10.1021/bi952910c.
48. Hebart H., Bollinger C., Fisch P., Sarfati J., Meisner C., Baur M., et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood 2002, 100:4521-4528. 10.1182/blood-2002-01-0265.
49. Heslop H.E., Ng C.Y., Li C., Smith C.A., Loftin S.K., Krance R.A., et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 1996, 2:551-555.
50. Heslop H.E., Slobod K.S., Pule M.A., Hale G.A., Rousseau A., Smith C.A., et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010, 115:925-935. 10.1182/blood-2009-08-239186.
51. Ito J.I., Lyons J.M. Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis. J. Infect. Dis. 2002, 186:869-871. 10.1086/342509.
52. Ito J.I., Lyons J.M., Hong T.B., Tamae D., Liu Y.-K., Wilczynski S.P., et al. Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f3 protect mice against invasive aspergillosis. Infect. Immun. 2006, 74:5075-5084. 10.1128/IAI.00815-06.
53. Jantunen E., Ruutu P., Niskanen L., Volin L., Parkkali T., Koukila-Kähkölä P., et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant. 1997, 19:801-808. 10.1038/sj.bmt.1700737.
54. Jolink H., Meijssen I.C., Hagedoorn R.S., Arentshorst M., Drijfhout J.W., Mulder A., et al. Characterization of the T-cell-mediated immune response against the Aspergillus fumigatus proteins Crf1 and catalase 1 in healthy individuals. J. Infect. Dis. 2013, 208:847-856. 10.1093/infdis/jit237.
55. Jolink H., Hagedoorn R.S., Lagendijk E.L., Drijfhout J.W., van Dissel J.T., Falkenburg J.H.F., et al. Induction of A. fumigatus-specific CD4-positive T cells in patients recovering from invasive aspergillosis. Haematologica 2014, 99:1255-1263. 10.3324/haematol.2013.098830.
56. Kalaitsidou M., Kueberuwa G., Schütt A., Gilham D.E. CAR T-cell therapy: toxicity and the relevance of preclinical models. Immunotherapy 2015, 7:487-497. 10.2217/imt.14.123.
57. Kauffman C.A. Clinical efficacy of new antifungal agents. Curr. Opin. Microbiol. 2006, 9:483-488. 10.1016/j.mib.2006.08.001.
58. Kerzerho J., Maazi H., Speak A.O., Szely N., Lombardi V., Khoo B., et al. Programmed cell death ligand 2 regulates TH9 differentiation and induction of chronic airway hyperreactivity. J. Allergy Clin. Immunol. 2013, 131:1048-1057. e1-2. 10.1016/j.jaci.2012.09.027.
59. Khanna N., Stuehler C., Conrad B., Lurati S., Krappmann S., Einsele H., et al. Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood 2011, 118:1121-1131. 10.1182/blood-2010-12-322610.
60. Kheradmand F., Kiss A., Xu J., Lee S.-H., Kolattukudy P.E., Corry D.B. A protease-activated pathway underlying Th cell type 2 activation and allergic lung disease. J. Immunol. 2002, 169:5904-5911.
61. Kim A., Nicolau D.P., Kuti J.L. Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States. Mycoses 2011, 54:e301-e312. 10.1111/j.1439-0507.2010.01903.x.
62. Kontoyiannis D.P., Marr K.A., Park B.J., Alexander B.D., Anaissie E.J., Walsh T.J., et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the transplant-associated infection surveillance network (TRANSNET) database. Clin. Infect. Dis. 2010, 50:1091-1100. 10.1086/651263.
63. Kumaresan P.R., Manuri P.R., Albert N.D., Maiti S., Singh H., Mi T., et al. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:10660-10665. 10.1073/pnas.1312789111.
64. Lange A., Dlubek D., Zdziarski R., Chodorowska A., Mordak-Domagala M., Klimczak A., et al. Donor lymphocyte infusions to leukemic bone lesions are therapeutically effective in a Ph+ ALL patient with post-HSCT relapse. J. Immunotoxicol. 2014, 11:347-352. 10.3109/1547691X.2014.893042.
65. Lass-Flörl C., Roilides E., Löffler J., Wilflingseder D., Romani L. Minireview host defence in invasive aspergillosis. Mycoses 2013, 56:403-413. 10.1111/myc.12052.
66. Latgé J.P. Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 1999, 12:310-350.
67. Leen A.M., Myers G.D., Sili U., Huls M.H., Weiss H., Leung K.S., et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 2006, 12:1160-1166. 10.1038/nm1475.
68. Lehrnbecher T., Beck O., Koehl U., Tramsen L. Cultivated anti-Aspergillus T(H) 1 cells. Med. Mycol. 2009, 47(Suppl. 1):S170-S174. 10.1080/13693780802169120.
69. Magee M.S., Snook A.E. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer. Discov. Med. 2014, 18:265-271.
70. Mahnke Y.D., Schwendemann J., Beckhove P., Schirrmacher V. Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells. Immunology 2005, 115:325-336. 10.1111/j.1365-2567.2005.02163.x.
71. Marr K.A., Carter R.A., Boeckh M., Martin P., Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002, 100:4358-4366. 10.1182/blood-2002-05-1496.
72. Marr K.A., Boeckh M., Carter R.A., Kim H.W., Corey L. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 2004, 39:797-802. 10.1086/423380.
73. Marr K.A. Fungal infections in hematopoietic stem cell transplant recipients. Med. Mycol. 2008, 46:293-302. 10.1080/13693780701885552.
74. Meuleman N., Ahmad I., Duvillier H., Lemort M., Bennani J., Martiat M., et al. Intrathecal donor lymphocyte infusion for the treatment of suspected refractory lymphomatous meningitis: a case report. Eur. J. Haematol. 2006, 77:523-526. 10.1111/j. 0902-4441.2006. t01-1-EJH2498.x.
75. Mikulska M., Raiola A.M., Bruno B., Furfaro E., Van Lint M.T., Bregante S., et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant. 2009, 44:361-370. 10.1038/bmt.2009.39.
76. Moen M.D., Lyseng-Williamson K.A., Scott L.J. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 2009, 69:361-392. 10.2165/00003495-200969030-00010.
77. Moosmann A., Bigalke I., Tischer J., Schirrmann L., Kasten J., Tippmer S., et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 2010, 115:2960-2970. 10.1182/blood-2009-08-236356.
78. Morgenstern D.E., Gifford M.A., Li L.L., Doerschuk C.M., Dinauer M.C. Absence of respiratory burst in X-linked chronic granulomatous disease mice leads to abnormalities in both host defense and inflammatory response to Aspergillus fumigatus. J. Exp. Med. 1997, 185:207-218.
79. Morrison B.E., Park S.J., Mooney J.M., Mehrad B. Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis. J. Clin. Invest. 2003, 112:1862-1870. 10.1172/JCI18125.
80. Mousset S., Buchheidt D., Heinz W., Ruhnke M., Cornely O.A., Egerer G., et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the infectious diseases working party (AGIHO) of the German society of hematology and oncology (DGHO). Ann. Hematol. 2014, 93:13-32. 10.1007/s00277-013-1867-1.
81. Muranski P., Boni A., Wrzesinski C., Citrin D.E., Rosenberg S.A., Childs R., et al. Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go?. Nat. Clin. Pract. Oncol. 2006, 3:668-681. 10.1038/ncponc0666.
82. Neofytos D., Horn D., Anaissie E., Steinbach W., Olyaei A., Fishman J., et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter prospective antifungal therapy (PATH) alliance registry. Clin. Infect. Dis. 2009, 48:265-273. 10.1086/595846.
83. Neofytos D., Treadway S., Ostrander D., Alonso C.D., Dierberg K.L., Nussenblatt V., et al. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. Transplant. Infect. Dis. 2013, 15:233-242. 10.1111/tid.12060.
84. Neumann M., Blau I.W., Burmeister T., Tietze-Buerger C., Blau O., Gerbitz A., et al. Intrathecal application of donor lymphocytes in leukemic meningeosis after allogeneic stem cell transplantation. Ann. Hematol. 2011, 90:911-916. 10.1007/s00277-011-1171-x.
85. Nierman W.C., Pain A., Anderson M.J., Wortman J.R., Kim H.S., Arroyo J., et al. Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature 2005, 438:1151-1156. 10.1038/nature04332.
86. Pagano L., Caira M., Nosari A., Van Lint M.T., Candoni A., Offidani M., et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin. Infect. Dis. 2007, 45:1161-1170. 10.1086/522189.
87. Papadopoulou A., Gerdemann U., Katari U.L., Tzannou I., Liu H., Martinez C., et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV Infections after HSCT. Sci. Transl. Med. 2014, 6:242ra83. 10.1126/scitranslmed.3008825.
88. Papadopoulou A., Krance R.A., Allen C.E., Lee D., Rooney C.M., Brenner M.K., et al. Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Mol. Ther. 2014, 22:1134-1138. 10.1038/mt.2014.48.
89. Park S.J., Hughes M.A., Burdick M., Strieter R.M., Mehrad B., Early N.K. cell-derived IFN- is essential to host defense in neutropenic invasive aspergillosis. J. Immunol. 2009, 182:4306-4312. 10.4049/jimmunol.0803462.
90. Passweg J.R., Baldomero H., Bader P., Bonini C., Cesaro S., Dreger P., et al. Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant. 2015, 10.1038/bmt.2014.312.
91. Peggs K.S., Verfuerth S., Pizzey A., Khan N., Guiver M., Moss P.A., et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003, 362:1375-1377. 10.1016/s0140-6736(03) 14634-x.
92. Perruccio K., Tosti A., Burchielli E., Topini F., Ruggeri L., Carotti A., et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005, 106:4397-4406. 10.1182/blood-2005-05-1775.
93. Perruccio K., Topini F., Tosti A., Gazzola M.V., Messina C., Martelli M.F., et al. Differences in Aspergillus-specific immune recovery between T-cell replete and T-cell depleted hematopoietic transplants. Eur. J. Haematol. 2015, 10.1111/ejh.12531.
94. Potenza L., Barozzi P., Vallerini D., Bosco R., Quadrelli C., Mediani L., et al. Diagnosis of invasive aspergillosis by tracking Aspergillus-specific T cells in hematologic patients with pulmonary infiltrates. Leukemia 2007, 21:578-581. 10.1038/sj.leu.2404504.
95. Potenza L., Vallerini D., Barozzi P., Riva G., Forghieri F., Beauvais A., et al. Characterization of specific immune responses to different Aspergillus antigens during the course of invasive Aspergillosis in hematologic patients. PLoS One 2013, 8:e74326. 10.1371/journal.pone.0074326.
96. Ramadan G., Konings S., Kurup V.P., Keever-Taylor C.A. Generation of Aspergillus- and CMV- specific T-cell responses using autologous fast DC. Cytotherapy 2004, 6:223-234. 10.1080/14653240410006040.
97. Rivera A., Hohl T.M., Collins N., Leiner I., Gallegos A., Saijo S., et al. Dectin-1 diversifies Aspergillus fumigatus-specific T cell responses by inhibiting T helper type 1CD4 T cell differentiation. J. Exp. Med. 2011, 208:369-381. 10.1084/jem.20100906.
98. Romani L., Fallarino F., De Luca A., Montagnoli C., D'Angelo C., Zelante T., et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 2008, 451:211-215. 10.1038/nature06471.
99. Romani L. Immunity to fungal infections. Nat. Rev. Immunol. 2011, 11:275-288. 10.1038/nri2939.
100. Rooney C.M., Smith C.A., Ng C.Y., Loftin S., Li C., Krance R.A., et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995, 345:9-13.
101. Rooney C.M., Smith C.A., Ng C.Y., Loftin S.K., Sixbey J.W., Gan Y., et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998, 92:1549-1555.
102. Roy R.M., Klein B.S. Dendritic cells in antifungal immunity and vaccine design. Cell Host Microbe 2012, 11:436-446. 10.1016/j.chom.2012.04.005.
103. Safdar A. Fungal cytoskeleton dysfunction or immune activation triggered by beta-glucan synthase inhibitors: potential mechanisms for the prolonged antifungal activity of echinocandins. Cancer 2009, 115:2812-2815. 10.1002/cncr.24323.
104. Sant A.J., McMichael A. Revealing the role of CD4(+) T cells in viral immunity. J. Exp. Med. 2012, 209:1391-1395. 10.1084/jem.20121517.
105. Segal B.H. Aspergillosis. N. Engl. J. Med. 2009, 360:1870-1884. 10.1056/NEJMra0808853.
106. Shoham S., Levitz S.M. The immune response to fungal infections. Br. J. Haematol. 2005, 129:569-582. 10.1111/j.1365-2141.2005.05397.x.
107. Storek J., Dawson M.A., Storer B., Stevens-Ayers T., Maloney D.G., Marr K.A., et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001, 97:3380-3389.
108. Stuehler C., Nowakowska J., Bernardini C., Topp M.S., Battegay M., Passweg J., et al. Multispecific Aspergillus T cells selected by CD137 or CD154 induce protective immune responses against the most relevant mold infections. J. Infect. Dis. 2014, 10.1093/infdis/jiu607.
109. Sucher A.J., Chahine E.B., Balcer H.E. Echinocandins the newest class of antifungals. Ann. Pharmacother. 2009, 43:1647-1657. 10.1345/aph.1M237.
110. Surh C.D., Sprent J. Homeostasis of naive and memory T cells. Immunity 2008, 29:848-862. 10.1016/j.immuni.2008.11.002.
111. Tacke D., Buchheidt D., Karthaus M., Krause S.W., Maschmeyer G., Neumann S., et al. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies.update of the recommendations of the infectious diseases working party of the German society for haematology and oncology. Ann. Hematol. 2014, 93:1449-1456. 10.1007/s00277-014-2108-y.
112. Thakur R., Anand R., Tiwari S., Singh A.P., Tiwary B.N., Shankar J. Cytokines induce effector T-helper cells during invasive aspergillosis; what we have learned about T-helper cells?. Front. Microbiol. 2015, 6(429). 10.3389/fmicb.2015.00429.
113. Tramsen L., Koehl U., Tonn T., Latgé J.-P., Schuster F.R., Borkhardt A., et al. Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy. Bone Marrow Transplant 2009, 43:13-19. 10.1038/bmt.2008.271.
114. Tramsen L., Schmidt S., Koehl U., Huenecke S., Latgé J.-P., Roeger F., et al. No effect of antifungal compounds on functional properties of human antifungal T-helper type 1 cells. Transpl. Infect. Dis. 2013, 15:430-434. 10.1111/tid.12089.
115. Tramsen L., Schmidt S., Roeger F., Schubert R., Salzmann-Manrique E., Latgé J.-P., et al. Immunosuppressive compounds exhibit particular effects on functional properties of human anti-Aspergillus Th1 cells. Infect. Immun. 2014, 82:2649-2656. 10.1128/IAI.01700-14.
116. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003, 3:133-146. 10.1038/nri1001.
117. Van Epps H.L., Feldmesser M., Pamer E.G. Voriconazole inhibits fungal growth without impairing antigen presentation or T-cell activation. Antimicrob. Agents Chemother. 2003, 47:1818-1823.
118. Vinh D.C., Sugui J.A., Hsu A.P., Freeman A.F., Holland S.M. Invasive fungal disease in autosomal-dominant hyper-IgE syndrome. J. Allergy Clin. Immunol. 2010, 125:1389-1390. 10.1016/j.jaci.2010.01.047.
119. Wüthrich M., Deepe G.S., Klein B. Adaptive immunity to fungi. Annu. Rev. Immunol. 2012, 30:115-148. 10.1146/annurev-immunol-020711-074958.
120. Wald A., Leisenring W., van Burik J.A., Bowden R.A. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J. Infect. Dis. 1997, 175:1459-1466.
121. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 1995, 333:1038-1044. 10.1056/nejm199510193331603.
122. Werner J.L., Metz A.E., Horn D., Schoeb T.R., Hewitt M.M., Schwiebert L.M., et al. Requisite role for the dectin-1 beta-glucan receptor in pulmonary defense against Aspergillus fumigatus. J. Immunol. 2009, 182:4938-4946. 10.4049/jimmunol.0804250.
123. Wiederhold N.P., Lewis R.E., Kontoyiannis D.P. Invasive aspergillosis in patients with hematologic malignancies. Pharmacotherapy 2003, 23:1592-1610.
124. Zelante T., De Luca A., Bonifazi P., Montagnoli C., Bozza S., Moretti S., et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur. J. Immunol. 2007, 37:2695-2706. 10.1002/eji.200737409.
125. Zhu F., Ramadan G., Davies B., Margolis D.A., Keever-Taylor C.A. Stimulation by means of dendritic cells followed by Epstein-Barr virus-transformed B cells as antigen-presenting cells is more efficient than dendritic cells alone in inducing Aspergillus f16-specific cytotoxic T cell responses. Clin. Exp. Immunol. 2008, 151:284-296. 10.1111/j.1365-2249.2007.03544.x.